Repligen Corporation

NasdaqGS:RGEN Voorraadrapport

Marktkapitalisatie: US$7.7b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Repligen Dividend

Dividend criteriumcontroles 0/6

Repligen heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

n/a

Uitbetalingsratio

Gemiddelde opbrengst industrie0.3%
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Winst per aandeel-US$0.034
Dividendrendementsvoorspelling0%

Recente dividendupdates

Geen updates

Recent updates

Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price

Sep 08
Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price

Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Jul 31
Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Jul 15
We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Repligen: Strong Filtration Growth, Offset By Other Challenges

Jul 13

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Jun 14
Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Jun 10
Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Repligen Stock: Still Quite Overvalued

May 30

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Apr 30
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Apr 15
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Feb 13
At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Jan 08
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Dec 19
Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Nov 01
What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Oct 17
Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Sep 29
Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Aug 09
Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Jul 17
Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

Jul 03
Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Jun 19
With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

May 23
Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Apr 11
Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

Mar 28
Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Mar 08
We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van RGEN in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van RGEN zijn gestegen.


Dividendrendement versus markt

Repligen Dividendrendement versus markt
Hoe verhoudt RGEN dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (RGEN)n/a
Markt onderkant 25% (US)1.4%
Markt Top 25% (US)4.3%
Gemiddelde industrie (Life Sciences)0.3%
Analist prognose (RGEN) (tot 3 jaar)0%

Opmerkelijk dividend: Het dividendrendement van RGEN kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van RGEN kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.


Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio RGEN te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat RGEN geen uitbetalingen heeft gerapporteerd.


Ontdek bedrijven met een sterk dividend